- Trials with a EudraCT protocol (978)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (2)
978 result(s) found for: Colorectal.
Displaying page 34 of 49.
| EudraCT Number: 2014-002417-36 | Sponsor Protocol Number: CAPTEM | Start Date*: 2014-08-28 | ||||||||||||||||
| Sponsor Name:Fondazione IRCCS Istituto Nazionale dei Tumori | ||||||||||||||||||
| Full Title: An open-label, randomized, multicenter, phase II trial designed to estimate the activity of CAPTEM combination versus FOLFIRI as second line treatment in patients who have progressed on or after fi... | ||||||||||||||||||
| Medical condition: colorectal cancer | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: IT (Completed) | ||||||||||||||||||
| Trial results: View results | ||||||||||||||||||
| EudraCT Number: 2019-002400-40 | Sponsor Protocol Number: FFCD1709 | Start Date*: 2020-07-27 |
| Sponsor Name:Fédération Francophone de Cancérologie Digestive | ||
| Full Title: A PROSPECTIVE, MULTICENTER, OPEN-LABEL, PHASE II STUDY TO EVALUATE EFFICACY AND SAFETY OF SELECTIVE INTERNAL RADIATION THERAPY PLUS XELOX, BEVACIZUMAB AND ATEZOLIZUMAB (IMMUNE CHEKPOINT INHIBITOR) ... | ||
| Medical condition: MICROSATELLITE STABLE (MSS) COLORECTAL CANCER WITH LIVER-DOMINANT METASTASIS | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: FR (Trial now transitioned) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2021-005110-34 | Sponsor Protocol Number: ICT01-102 | Start Date*: 2022-02-08 | ||||||||||||||||||||||||||
| Sponsor Name:ImCheck Therapeutics, Inc. | ||||||||||||||||||||||||||||
| Full Title: A two-part, open-label, clinical study to assess the safety, tolerability and activity of intravenous doses of ICT01 in combination with low-dose subcutaneous interleukin-2 in patients with advance... | ||||||||||||||||||||||||||||
| Medical condition: Relapsed/refractory patients with advanced solid tumors : metastatic colorectal cancer (CRC) or metastatic ovarian cancer or metastatic castration-resistant prostate cancer (mCRPC) or metastatic pa... | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
| Trial protocol: FR (Trial now transitioned) DE (Trial now transitioned) | ||||||||||||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||||||||||||
| EudraCT Number: 2020-005437-32 | Sponsor Protocol Number: ERASE-TMZ | Start Date*: 2021-03-10 | ||||||||||||||||
| Sponsor Name:FONDAZIONE IRCCS "ISTITUTO NAZIONALE DEI TUMORI" | ||||||||||||||||||
| Full Title: Temozolomide and irinotecan consolidation in patients with MGMT silenced, microsatellite stable colorectal cancer with persistence of minimal residual disease in liquid biopsy after standard adjuva... | ||||||||||||||||||
| Medical condition: Stage II (pT4)/III colorectal cancer with positive circulating tumor DNA (ctDNA) after oxaliplatin-based adjuvant chemotherapy | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: IT (Trial now transitioned) | ||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||
| EudraCT Number: 2012-003638-18 | Sponsor Protocol Number: AG0112CR | Start Date*: 2013-03-13 |
| Sponsor Name:Australasian Gastro-Intestinal Trials Group, Sydney University | ||
| Full Title: Randomised Phase II study of cetuximab alone or in combination with irinotecan in patients with metastatic CRC with either KRAS WT or G13D mutation. ICE CREAM: The Irinotecan Cetuximab Evaluation a... | ||
| Medical condition: metastatic colorectal cancer | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: GB (GB - no longer in EU/EEA) ES (Completed) IT (Completed) BE (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2018-001600-12 | Sponsor Protocol Number: 20177097 | Start Date*: 2019-05-29 | |||||||||||
| Sponsor Name:Dipartimento di Medicina di Precisione - Università degli studi della Campania "L. Vanvitelli" | |||||||||||||
| Full Title: Phase II randomized study evaluating the efficacy of panitumumab (VEctibix) and Trifluridine-Tipiracil (LOnsurf) in pretreated RAS wild type metastatic colorectal cancer patients: the VELO trial | |||||||||||||
| Medical condition: mCRC | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: IT (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2019-004987-23 | Sponsor Protocol Number: RAS-Triplet | Start Date*: 2020-05-22 |
| Sponsor Name:UMC Utrecht | ||
| Full Title: A Dose-Escalating Phase I/II Study in Patients with RAS-Mutated Metastatic Colorectal Cancer to Investigate Safety and Clinical Activity of the Triple Combination of: MEK-inhibitor binimetinib, Pan... | ||
| Medical condition: colorectal cancer | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: NL (Trial now transitioned) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2018-000347-60 | Sponsor Protocol Number: TTD-18-01 | Start Date*: 2018-08-08 | |||||||||||
| Sponsor Name:Grupo de Tratamiento de los Tumores Digestivos (TTD) | |||||||||||||
| Full Title: Phase III randomized sequential open-label study to evaluate the efficacy of FOLFOX + panitumumab followed by FOLFIRI + bevacizumab (Sequence 1) versus FOLFOX + bevacizumab followed by FOLFIRI + pa... | |||||||||||||
| Medical condition: metastatic colorectal cancer | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: ES (Trial now transitioned) PT (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2006-006175-20 | Sponsor Protocol Number: ACCORD 15/0608 - PRODIGE 7 | Start Date*: 2009-05-11 | |||||||||||
| Sponsor Name:FNCLCC | |||||||||||||
| Full Title: Essai de phase III évaluant la place de la ChimioHyperthermie IntraPéritonéale per opératoire (CHIP) après résection maximale d'une carcinose péritonéale d'origine colorectale associée à une chimi... | |||||||||||||
| Medical condition: Notre étude multicentrique de phase III a donc pour objet de définir véritablement la place de la chimiohyperthermie intra-péritonéale en la randomisant chez ces patients ayant pu bénéficier d’une ... | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: FR (Completed) ES (Ongoing) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2011-000840-70 | Sponsor Protocol Number: MACBETH | Start Date*: 2011-08-19 | |||||||||||
| Sponsor Name:G.O.N.O. - GRUPPO ONCOLOGICO NORD OVEST | |||||||||||||
| Full Title: INDUCTION CHEMOTHERAPY WITH FOLFOXIRI PLUS CETUXIMAB AND MAINTENANCE WITH CETUXIMAB OR BEVACIZUMAB THERAPY IN UNRESECTABLE KRAS WILD-TYPE METASTATIC COLORECTAL CANCER PATIENTS | |||||||||||||
| Medical condition: UNRESECTABLE KRAS WILD-TYPE METASTATIC COLORECTAL CANCER PATIENTS | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: IT (Ongoing) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2014-002063-14 | Sponsor Protocol Number: GEMCAD-1402 | Start Date*: 2014-10-23 | |||||||||||
| Sponsor Name:GEMCAD (Grupo Español Multidisciplinar en Cáncer Digestivo) | |||||||||||||
| Full Title: Induction FOLFOX with or without Aflibercept followed by chemoradiation in High Risk Locally Advanced Rectal Cancer. Phase II randomized, multicenter, open label trial | |||||||||||||
| Medical condition: Patients with high risk locally advanced rectal carcinoma (defined by Magnetic Resonance Imaging [MRI]), who are candidates for multimodality treatment. | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: ES (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2017-000292-83 | Sponsor Protocol Number: Tallisur | Start Date*: 2017-08-30 |
| Sponsor Name:Servier Deutschland GmbH | ||
| Full Title: Prospective, Multicenter, Open-label Phase IV trial of Trifluridine/Tipiracil to Evaluate the Health-related Quality of Life in Patients with Metastatic Colorectal Cancer | ||
| Medical condition: Histologically or cytologically confirmed UICC stage IV carcinoma of colon or rectum with metastasis (metastatic colorectal cancer) with need for treatment due to progression | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: DE (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2016-004575-49 | Sponsor Protocol Number: FFCD-1603 | Start Date*: 2017-07-11 |
| Sponsor Name:Federation Francophone de Cancerologie Digestive | ||
| Full Title: MULTICENTER RANDOMIZED PHASE II STUDY COMPARING THE EFFECTIVENESS AND TOLERANCE OF AVELUMAB VERSUS STANDARD 2nd LINE TREATMENT CHEMOTHERAPY IN PATIENTS WITH COLORECTAL METASTATIC CANCER WITH MICROS... | ||
| Medical condition: COLORECTAL METASTATIC CANCER WITH MICROSATELLITE INSTABILITY (MSI) | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: FR (Trial now transitioned) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2016-001493-15 | Sponsor Protocol Number: UC-0110/1610 | Start Date*: 2017-10-13 |
| Sponsor Name:UNICANCER | ||
| Full Title: A randomized phase II study comparing treatment intensification with hepatic arterial infusion chemotherapy plus systemic chemotherapy to systemic chemotherapy alone in patients with liver-only col... | ||
| Medical condition: Patients with liver-only non resectable colorectal metastases. | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: FR (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2015-000481-58 | Sponsor Protocol Number: MLN0002SC-3031 | Start Date*: 2016-01-22 | |||||||||||
| Sponsor Name:Takeda Development Centre Europe, Ltd. | |||||||||||||
| Full Title: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Vedolizumab Subcutaneous as Maintenance Therapy in Subjects With Moderately to Severely Active Cr... | |||||||||||||
| Medical condition: Crohn’s Disease | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: SK (Completed) CZ (Completed) NL (Completed) BG (Completed) GB (Completed) DE (Completed) BE (Completed) SE (Completed) DK (Completed) LT (Completed) HU (Completed) ES (Completed) IT (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2012-000427-41 | Sponsor Protocol Number: CPPFAP-310 | Start Date*: 2014-05-15 |
| Sponsor Name:Cancer Prevention Pharmaceuticals, Inc. | ||
| Full Title: A Double-Blind, Randomized, Phase III Trial of the Safety and Efficacy of CPP-1X/Sulindac Compared With CPP-1X, Sulindac as Single Agents in Patients with Familial Adenomatous Polyposis (FAP) | ||
| Medical condition: Familial Adenomatous Polyposis (FAP) | ||
| Disease: | ||
| Population Age: Adults | Gender: Male, Female | |
| Trial protocol: GB (Completed) DE (Completed) NL (Completed) ES (Completed) BE (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2021-002823-40 | Sponsor Protocol Number: NOUS-209-01 | Start Date*: 2021-12-21 | |||||||||||
| Sponsor Name:Nouscom S.r.l. | |||||||||||||
| Full Title: A Phase I/IIa, Multicenter, Open-Label Study of Nous-209 Genetic Vaccine for the Treatment of Microsatellite Unstable Solid Tumors | |||||||||||||
| Medical condition: Locally advanced unresectable or metastatic, microsatellite instability high (MSI-H) or dMMR CRC who are eligible for anti-PD-1 1st line of treatment | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: ES (Ongoing) IT (Trial now transitioned) BE (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2019-004196-39 | Sponsor Protocol Number: UC-GIG-1910 | Start Date*: 2020-07-23 | |||||||||||
| Sponsor Name:UNICANCER | |||||||||||||
| Full Title: A randomized, phase II study comparing the sequences of regorafenib and trifluridine/tipiracil, after failure of standard therapies in patients with metastatic colorectal cancer | |||||||||||||
| Medical condition: The study population will consist of male and female patients aged ≥ 18 years old with metastatic colorectal cancer after failure of fluoropyrimidine-, irinotecan-, and oxaliplatin-based chemothera... | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: FR (Completed) BE (Completed) IT (Prematurely Ended) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2011-004426-10 | Sponsor Protocol Number: MO28072 | Start Date*: 2012-05-11 | |||||||||||||||||||||||||||||||||||||||||
| Sponsor Name:F. Hoffman-La Roche Ltd. | |||||||||||||||||||||||||||||||||||||||||||
| Full Title: An open-label, phase II study of vemurafenib in patients with BRAF V600 mutation-positive cancers | |||||||||||||||||||||||||||||||||||||||||||
| Medical condition: Patients with cancers (excluding melanoma and papillary thyroid cancer) harboring BRAF V600 mutations as identified by the routinely performed mutation analysis assays at each individual partici... | |||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||
| Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||||||||||||
| Trial protocol: GB (Completed) ES (Completed) DE (Completed) | |||||||||||||||||||||||||||||||||||||||||||
| Trial results: View results | |||||||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2016-004678-16 | Sponsor Protocol Number: INCB24360-207 | Start Date*: 2018-05-31 | |||||||||||||||||||||||||||||||||||||||||
| Sponsor Name:Incyte Corporation | |||||||||||||||||||||||||||||||||||||||||||
| Full Title: A Phase 1/2, Open-Label, Safety, Tolerability, and Efficacy Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Subjects With Advanced or Metastatic Solid Tumors | |||||||||||||||||||||||||||||||||||||||||||
| Medical condition: Subjects with solid tumors of the type of colorectal cancer, pancreatic ductal adenocarcinoma, Squamous non-small cell lung cancer, non-squamous non-small cell lung cancer, any solid tumor that pro... | |||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||||||||||||
| Trial protocol: ES (Prematurely Ended) | |||||||||||||||||||||||||||||||||||||||||||
| Trial results: View results | |||||||||||||||||||||||||||||||||||||||||||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.